Cargando…
Myasthenia Gravis as an Immune-Mediated Side Effect of Checkpoint Inhibitors
This is a case report of new-onset myasthenia gravis (MG) as an immune-mediated adverse event (irAE) related to the use of pembrolizumab in a patient with undifferentiated adenocarcinoma of the pancreato-biliary tract. Up to this moment, only 52 cases of new-onset MG have been related to immune chec...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275066/ https://www.ncbi.nlm.nih.gov/pubmed/34277306 http://dx.doi.org/10.7759/cureus.16316 |